138 related articles for article (PubMed ID: 19203501)
1. A new mouse model resembling human diabetic nephropathy: uncoupling of VEGF with eNOS as a novel pathogenic mechanism.
Nakagawa T
Clin Nephrol; 2009 Feb; 71(2):103-9. PubMed ID: 19203501
[TBL] [Abstract][Full Text] [Related]
2. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
Nakagawa T; Sato W; Glushakova O; Heinig M; Clarke T; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Johnson RJ; Croker B
J Am Soc Nephrol; 2007 Feb; 18(2):539-50. PubMed ID: 17202420
[TBL] [Abstract][Full Text] [Related]
3. Uncoupling of VEGF with NO as a mechanism for diabetic nephropathy.
Nakagawa T
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S67-9. PubMed ID: 18926584
[TBL] [Abstract][Full Text] [Related]
4. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy.
Sato W; Kosugi T; Zhang L; Roncal CA; Heinig M; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Grant MB; Croker BP; Nakagawa T
Lab Invest; 2008 Sep; 88(9):949-61. PubMed ID: 18607348
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice.
Kanetsuna Y; Takahashi K; Nagata M; Gannon MA; Breyer MD; Harris RC; Takahashi T
Am J Pathol; 2007 May; 170(5):1473-84. PubMed ID: 17456755
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of calmodulin in pancreatic beta cells induces diabetic nephropathy.
Yuzawa Y; Niki I; Kosugi T; Maruyama S; Yoshida F; Takeda M; Tagawa Y; Kaneko Y; Kimura T; Kato N; Yamamoto J; Sato W; Nakagawa T; Matsuo S
J Am Soc Nephrol; 2008 Sep; 19(9):1701-11. PubMed ID: 18525005
[TBL] [Abstract][Full Text] [Related]
7. Endothelial nitric oxide synthase.
Nakagawa T; Johnson RJ
Contrib Nephrol; 2011; 170():93-101. PubMed ID: 21659762
[TBL] [Abstract][Full Text] [Related]
8. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice.
Zhao HJ; Wang S; Cheng H; Zhang MZ; Takahashi T; Fogo AB; Breyer MD; Harris RC
J Am Soc Nephrol; 2006 Oct; 17(10):2664-9. PubMed ID: 16971655
[TBL] [Abstract][Full Text] [Related]
9. Mouse models of diabetic nephropathy.
Alpers CE; Hudkins KL
Curr Opin Nephrol Hypertens; 2011 May; 20(3):278-84. PubMed ID: 21422926
[TBL] [Abstract][Full Text] [Related]
10. Imbalance of glomerular VEGF-NO axis in diabetic rats: prevention by chronic therapy with propyl gallate.
Tian S; Gan Y; Li J; Wang L; Shen J; Liu T; Ye T; Liu H; Liu D; Deng Y; Wang W
J Nephrol; 2011; 24(4):499-506. PubMed ID: 21425119
[TBL] [Abstract][Full Text] [Related]
11. Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.
Veron D; Bertuccio CA; Marlier A; Reidy K; Garcia AM; Jimenez J; Velazquez H; Kashgarian M; Moeckel GW; Tufro A
Diabetologia; 2011 May; 54(5):1227-41. PubMed ID: 21318407
[TBL] [Abstract][Full Text] [Related]
12. Endothelial cell-specific overexpression of endothelial nitric oxide synthase in Ins2Akita mice exacerbates diabetic nephropathy.
Natarajan M; Habib SL; Reddick RL; Delma CR; Manickam K; Prihoda TJ; Werner SL; Mohan S
J Diabetes Complications; 2019 Jan; 33(1):23-32. PubMed ID: 30424931
[TBL] [Abstract][Full Text] [Related]
13. Early Enhanced Leucine-Rich
Haku S; Wakui H; Azushima K; Haruhara K; Kinguchi S; Ohki K; Uneda K; Kobayashi R; Matsuda M; Yamaji T; Yamada T; Minegishi S; Ishigami T; Yamashita A; Ohashi K; Tamura K
Biomed Res Int; 2018; 2018():2817045. PubMed ID: 30515388
[TBL] [Abstract][Full Text] [Related]
14. Podocyte-specific VEGF-a gain of function induces nodular glomerulosclerosis in eNOS null mice.
Veron D; Aggarwal PK; Velazquez H; Kashgarian M; Moeckel G; Tufro A
J Am Soc Nephrol; 2014 Aug; 25(8):1814-24. PubMed ID: 24578128
[TBL] [Abstract][Full Text] [Related]
15. Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.
Tanabe K; Lanaspa MA; Kitagawa W; Rivard CJ; Miyazaki M; Klawitter J; Schreiner GF; Saleem MA; Mathieson PW; Makino H; Johnson RJ; Nakagawa T
Am J Physiol Renal Physiol; 2012 May; 302(9):F1151-60. PubMed ID: 22338086
[TBL] [Abstract][Full Text] [Related]
16. Comparison of diabetic nephropathy between male and female eNOS
Ma Y; Li W; Yazdizadeh Shotorbani P; Dubansky BH; Huang L; Chaudhari S; Wu P; Wang LA; Ryou MG; Zhou Z; Ma R
Am J Physiol Renal Physiol; 2019 May; 316(5):F889-F897. PubMed ID: 30810354
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?
Balakumar P; Chakkarwar VA; Krishan P; Singh M
Biomed Pharmacother; 2009 Mar; 63(3):171-9. PubMed ID: 18823739
[TBL] [Abstract][Full Text] [Related]
18. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease.
Nakagawa T
Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1665-72. PubMed ID: 17545302
[TBL] [Abstract][Full Text] [Related]
19. The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.
Bus P; Scharpfenecker M; Van Der Wilk P; Wolterbeek R; Bruijn JA; Baelde HJ
Diabetologia; 2017 Sep; 60(9):1813-1821. PubMed ID: 28620823
[TBL] [Abstract][Full Text] [Related]
20. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy.
Wang CH; Li F; Hiller S; Kim HS; Maeda N; Smithies O; Takahashi N
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):2070-5. PubMed ID: 21245338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
